Skip to main content

Market Overview

Sigilon Therapeutics' Fabry Disease Therapy Receives Orphan Drug Designation In US

  • The FDA has designated Orphan Drug Status to Sigilon Therapeutics Inc's (NASDAQ: SGTX) SIG-007 to treat Fabry disease.
  • It is a rare genetic disorder caused by AGAL deficiency and the accumulation of specific substrates within a patient's cells, contributing to multi-organ complications.
  • SIG-007 comprises genetically modified cells with a non-viral vector to express human alpha-galactosidase A or AGAL.
  • Among the benefits of Orphan Drug designation in the U.S. is seven years of market exclusivity for the indication, if approved.
  • Price Action: SGTX shares closed 19.5% lower at $21.86 on Thursday.

Related Articles (SGTX)

View Comments and Join the Discussion!

Posted-In: Fabry diseaseBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at